The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Session highlights: PNH, SCD, and thalassemia
Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, highlights some of the presentations given during a session at BSH 2022, drawing focus on three main areas: paroxysmal nocturnal hemoglobinuria (PNH), thalassemia, and sickle cell disease (SCD). Dr Chakravorty first discusses the use of eculizumab and pegcetacoplan for the treatment of PNH, and further highlights two clinical trials in this area. Following this, Dr Chakravorty discusses a study which focused on genotype and clinical characterization of thalassemia in Malaysian patients, and concludes by highlighting a presentation that was given on acute pain management in SCD. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Advisory board – GBT, Forma, Novartis
